| Patient | Lou Gehrig |
|---|---|
| Date of birth | 1990-06-19 |
| Identifiers | MRN HR-ET018-SYN; SSN (made up) 000-18-6620 |
| Document date | 2026-05-18 |
| Author | Gavin Hollister, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Neuromuscular consultation with EMG and nerve conduction studies, and results of the MRI and blood tests. [S]
Mr. Gehrig returns two weeks after his first visit and is seen the same day by Dr. Nakamura of neuromuscular neurology, who performed EMG and nerve conduction studies this morning. The MRI of the brain and cervical spine a week ago was normal. Since the first visit he has had no new symptoms but feels his grip is a little weaker; he has kept to walking and stretching and has not played or lifted. He has no trouble speaking, swallowing or breathing. He asked to hear the results himself first, and plainly. [S]
| Element | Detail |
|---|---|
| Tests | EMG and nerve conduction studies this morning; MRI of the brain and cervical spine a week ago |
| Symptoms | Grip slightly weaker; cramps; no speech, swallowing or breathing symptoms |
| Activity | Not playing or lifting; walking and stretching |
| His request | Results to him first, plainly |
| System | Result | Finding |
|---|---|---|
| Neurological | Positive | Hand and left ankle weakness; cramps and twitching; no numbness |
| Ears, nose, mouth, and throat | Negative | No slurred speech, choking or drooling |
| Respiratory | Negative | No breathlessness, including lying flat; no morning headaches |
| Psychiatric | Positive | Worried and sleeping less while waiting for results; no thoughts of self-harm |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Riluzole 50 mg oral tablet, one tablet by mouth twice daily, an hour before or two hours after meals | One tablet by mouth every 12 hours on an empty stomach | Oral route | 2026-05-18 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-05-18 | Body height | 183 | cm | S |
| 2026-05-18 | Body weight | 89.2 | kg | S |
| 2026-05-18 | Body mass index (BMI) [Ratio] | 26.6 | kg/m2 | S |
| 2026-05-18 | Systolic blood pressure | 122 | mm[Hg] | S |
| 2026-05-18 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-05-18 | Heart rate | 70 | /min | S |
| 2026-05-18 | Respiratory rate | 14 | /min | S |
| 2026-05-18 | Body temperature | 36.6 | Cel | S |
| 2026-05-18 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-05-18 | Forced vital capacity [Volume] Respiratory system | 4.52 | L | >=4.1 L | Normal | S |
| 2026-05-18 | FVC measured/predicted | 88 | % | 80% of predicted or more is normal; noninvasive ventilation is considered below 50% | Normal | S |
| 2026-05-18 | Total score [ALSFRS-R] | 42 | {score} | S | ||
| 2026-05-18 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | {score} | S |
Vital signs recorded on 2026-05-18; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 122/76, pulse 70; weight 89.2 kg |
| Neurological | Examined with Dr. Nakamura: wasting of the first dorsal interosseous and thenar muscles, left more than right; fasciculations in both arms, thighs and calves; grip and finger abduction 4/5 on the right and 4-/5 on the left; left ankle dorsiflexion 4-/5; reflexes brisk with spread, Hoffmann sign present on both sides, left plantar extensor; jaw jerk normal; tongue normal; sensation normal |
| Respiratory | No accessory muscle use; normal chest expansion |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Progressive weakness and loss of coordination for about a year: fumbling with buttons and a bat, tripping on curbs, a fall on the ice in the winter, muscle cramps and twitching in the arms and thighs; no numbness, pain, double vision, or trouble speaking or swallowing. Examination: wasting of the hand muscles (left more than right), fasciculations in both arms and thighs, weakness of grip and of left ankle dorsiflexion, brisk reflexes with spread and a positive Hoffmann sign, normal sensation. Mixed upper and lower motor neuron signs; evaluation for motor neuron disease and its mimics begun, with neuromuscular neurology consultation booked | resolved | confirmed | M62.81 | S — Synthetic presenting problem anchored to his documented decline in 1938 and 1939; superseded by the diagnosis. |
| Amyotrophic lateral sclerosis, limb onset: progressive weakness for about a year with upper and lower motor neuron signs in the cervical and lumbosacral regions, and active and chronic denervation on EMG in the cervical, thoracic and lumbosacral regions with normal sensory nerve conduction; MRI of the brain and cervical spine and blood tests exclude mimics. Meets the Gold Coast criteria and the revised El Escorial category of clinically probable ALS. ALSFRS-R 42 and FVC 88% of predicted at diagnosis. Synthetic modern episode linked to his documented diagnosis | active | confirmed | G12.21 | S — Synthetic modern diagnosis; the documented 1939 diagnosis is the anchor. EMG findings, scores and timing are synthetic. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Upper and lower motor neuron examination by region | At diagnosis, then every visit | Completed today | Upper and lower motor neuron signs in the cervical and lumbosacral regions; bulbar region normal |
| Imaging | EMG and nerve conduction studies | At diagnosis | Completed today | Active and chronic denervation in three regions; normal sensory conduction; no conduction block |
| Imaging | MRI of the brain and cervical spine | At diagnosis, to exclude mimics | Completed today | Normal; no cord compression |
| Laboratory | Blood tests to exclude mimics | At diagnosis | Completed today | Calcium, B12, TSH, A1c normal at intake; no monoclonal protein; HIV negative; creatine kinase 412 U/L |
| Survey | ALSFRS-R | Every 2 to 3 months in the multidisciplinary ALS clinic | Completed today | 42 of 48 at diagnosis |
| Imaging | Seated forced vital capacity | Every 2 to 3 months in the multidisciplinary ALS clinic | Completed today | 4.52 L, 88% of predicted |
| Examination | Maximal inspiratory pressure; supine capacity and overnight oximetry when values fall or symptoms appear | Every 2 to 3 months in the multidisciplinary ALS clinic | Completed today | Maximal inspiratory pressure -86 cmH2O; no orthopnea |
| Examination | Weight and BMI (gastrostomy discussion if weight falls 5 to 10% or swallowing is unsafe; place while FVC is above 50%) | Every visit | Completed today | 89.2 kg, BMI 26.6 |
| Examination | Speech and swallowing assessment | Every 2 to 3 months in the multidisciplinary ALS clinic | Completed today | Speech and swallowing normal |
| Survey | Cognitive and behavioral screening | At diagnosis and periodically | Completed today | Brief cognitive screen normal; no behavioral change reported by him |
| Survey | Depression (PHQ-9) | Every visit | Completed today | PHQ-9 7, mild; no thoughts of self-harm |
| Laboratory | ALT on riluzole | Monthly for 3 months, then every 3 months | Due | Baseline ALT 32 U/L at intake; riluzole starts today |
| Laboratory | Genetic testing (SOD1 result decides tofersen) | Offer at diagnosis to every person with ALS | Ordered | Panel sent today after genetic counseling |
| Referral | Neuromuscular neurology and multidisciplinary ALS clinic | At diagnosis, then every 2 to 3 months | Completed today | Seen by Dr. Nakamura today; clinic enrolment |
| Self-management | Advance care planning | Early, then at each change | Due | Introduced today; to be held when he is ready |
Goal progress:
Guideline basis: Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review) (2009); Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review) (2009); A proposal for new diagnostic criteria for ALS (Gold Coast criteria) (2020); El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis (2000); Evidence-based consensus guidelines for ALS genetic testing and counseling (2023)
Follow-up: Genetic counseling follow-up when the result returns. First full ALS clinic visit in about five weeks, with primary care the following week. Next scheduled visit 2026-06-29: six weeks after diagnosis: riluzole safety, genetic test result, multidisciplinary ALS clinic, mobility, mood, and his decision about work. [S]